Overview:

A promising biomarker can fail for two very different reasons: the assay may not measure it consistently, or the result may not predict the clinical outcome that matters. Using a hypothetical blood-based marker intended to identify treatment responders, this article shows how analytical validation, clinical validation and qualification address those gaps—and how aligning the evidence with the intended use can prevent costly studies from answering the wrong question.

What Is Biomarker Validation?

Finding a biological signal is only the start. Before a biomarker can guide research or care, teams need to know that the signal can be measured consistently and that the result means something in the intended setting. Validation builds that evidence.¹

The standard rises with the stakes. An exploratory study may need enough confidence to prioritize a candidate. A diagnostic or treatment-selection program needs evidence that the measurement is reliable, clinically relevant and appropriate for the population and decision at hand.¹

Biomarker validation is not a single test or milestone. It is a progression in which different forms of evidence answer different questions. Consider a hypothetical blood-based biomarker intended to identify patients likely to respond to a therapy: analytical validation asks whether the assay measures the marker accurately and reproducibly; clinical validation asks whether the measured values distinguish responders from nonresponders in the intended population; and qualification asks whether the combined evidence supports using the marker for that defined decision.²

Understanding the Biomarker Development Pathway

The pathway is often drawn as a straight line, but real programs rarely move so neatly. Discovery, verification, validation and qualification can overlap, and new evidence may send teams back to refine an assay or narrow the intended use. What matters is the decision at each stage: Is the signal worth pursuing? Can it be reproduced? Can it be measured reliably? Does it track with the outcome of interest? Is the evidence strong enough for the proposed use?³

Biomarker Discovery

Discovery casts a wide net for signals linked to a biological process, disease state or treatment response. Genomics, transcriptomics, proteomics, metabolomics and imaging can surface many candidates, but at this point they are leads—not validated biomarkers.⁴

The immediate task is to decide which signals deserve another look. Biological plausibility, effect size, statistical support and relevance to the intended outcome help narrow the field.⁴

Verification

Verification asks whether the signal survives a change in samples, datasets or methods. A candidate that disappears outside the discovery experiment is unlikely to justify a larger validation program.⁵

Independent cohorts, targeted assays, orthogonal methods and replication studies can expose findings driven by a single dataset or experimental condition. Candidates that hold up move forward; those that do not should be revised or dropped.⁵

Validation

Validation tests whether the biomarker and its measurement method can support the intended purpose. For the blood-based treatment-response example, this means first showing that the assay performs reliably and then determining whether the measured result is associated with treatment response in the target population.

Qualification

Qualification evaluates whether the accumulated biological, analytical and clinical evidence supports a specific context of use. In the running example, evidence that the assay is reliable and associated with response would not automatically support every application; it would need to justify the defined use of identifying likely responders in the specified population.⁶

Clinical Implementation

Implementation is where a supported biomarker meets routine practice—whether in diagnostic testing, patient stratification, treatment selection or disease monitoring.⁷

Strong evidence does not guarantee adoption. A test may still falter if laboratories cannot standardize it, results take too long, costs are impractical or reports do not fit the clinical workflow. These operational constraints belong in the development plan, not as an afterthought.⁷

What Is Analytical Validation?

Analytical validation puts the assay under pressure. The exact tests depend on the biomarker, platform, sample type and intended use, but the aim is practical: define where the method performs reliably and where it does not. Common characteristics include accuracy, precision, sensitivity, specificity, linearity, analytical range and robustness.^8,9

• Accuracy describes how closely an assay's measurements agree with a known or accepted value.
• Precision describes how closely repeated measurements agree with one another. It may be assessed within a single run and across different runs, operators, instruments or days.
• Sensitivity refers to the ability of an assay to detect the biomarker even at low concentrations.
• Specificity describes the ability of an assay to measure the intended biomarker without being substantially affected by other substances or signals in the sample.
• Linearity assesses whether signal intensity is proportional to the concentration of the biomarker across a defined interval.
• Analytical range defines the concentrations over which the assay can produce reliable measurements.
• Robustness evaluates whether assay performance remains consistent when small, deliberate variations are introduced into experimental conditions.

Other characteristics, such as detection and quantification limits, recovery, sample stability, carryover and interference, may also be evaluated depending on the assay and its intended application.¹⁰

For the hypothetical treatment-response biomarker, analytical validation would test whether results remain accurate and reproducible across relevant concentrations, sample conditions, runs, operators and instruments. If those measurements vary beyond predefined limits, a later clinical association may reflect assay noise rather than biology.

Analytical Validation vs Clinical Validation vs Qualification

Biomarker Validation Bioanalytical Workflows

A sound assay can still produce misleading data if the surrounding workflow is weak. Collection, handling, analysis and reporting all shape the result, so control must extend from the first sample to the final dataset. Key stages include:

Sample Collection and Handling

Preanalytical variation can overwhelm a genuine biological signal. Collection tubes, processing delays, storage conditions and freeze–thaw cycles should therefore be controlled and documented across sites.³

Assay Development

Method choice starts with the biological question and sample matrix. The assay must detect—or quantify—the biomarker at concentrations relevant to the proposed use, not simply under ideal laboratory conditions.³

Method Optimization

Optimization is the point to remove avoidable sources of variation. Teams may adjust sample preparation, reagent conditions or instrument settings until the method is stable enough for formal validation.³

Quality Control

Quality controls provide an early warning when performance drifts. Reference materials and predefined acceptance criteria make it easier to separate a true biological result from an analytical problem.³

Data Analysis and Documentation

Analytical data are reviewed and analyzed according to established methods, with deviations and quality issues documented appropriately. Before analyzing the data, a study might specify:¹¹

• How measurements will be calculated or normalized
• Which samples should be excluded and under what circumstances
• How missing or outlier data will be handled
• What acceptance criteria must the assay meet
• Which statistical methods will be used
• How deviations from the protocol will be recorded

Clinical Validation Explained

Clinical validation establishes whether a biomarker is meaningfully associated with a defined disease state, biological process, clinical characteristic or patient outcome. For the hypothetical blood-based treatment-response biomarker, the study would test whether measured values distinguish responders from nonresponders in a population that reflects the intended treatment setting. Depending on the intended use, researchers may assess predictive performance, define a clinically relevant threshold and determine whether the relationship holds across relevant patient subgroups.²

The evidence should reflect the biomarker’s intended population and use. In the running example, disease stage, prior treatment, sample-collection timing and therapy regimen could all influence the apparent association with response. Prespecifying these variables helps determine whether the biomarker is genuinely predictive in the intended setting rather than simply associated with differences between study groups.²

What Is Biomarker Qualification?

Biomarker qualification is the process of establishing, based on a body of evidence, that a biomarker can be used for a particular purpose, such as supporting drug development, assessing a biological response or identifying a patient population.⁶

Qualification differs from clinical validation in its focus. Clinical validation would establish an association between the blood-based marker and treatment response; qualification would integrate the biological, analytical and clinical evidence to determine whether the marker can be relied on to identify likely responders for the defined therapy and population.¹²

That context is deliberately narrow. Evidence supporting the marker for selecting patients before treatment would not automatically qualify it for monitoring response after treatment, use with another therapy or application in a different disease stage.¹²

Designing Fit-for-Purpose Biomarker Studies

Fit-for-purpose does not mean lowering the bar. It means matching the evidence to the decision. An exploratory marker used to rank candidates does not require the same package as a marker used to select patients, but both need clearly justified performance expectations.

Defining Intended Use

The first step is to state clearly what the biomarker is intended to do. For the running example, the proposed use is to identify, before treatment, patients with a defined condition who are more likely to respond to a specific therapy. That statement guides the selection of the assay, samples, study population, comparator, endpoint and performance criteria.¹³

Selecting Validation Criteria

Validation criteria should follow from that use. The assay would need adequate precision, sensitivity, specificity and stability across the clinically relevant concentration range, while the clinical study would need predefined measures of how well the marker separates likely responders from nonresponders. Not every biomarker requires the same parameters or degree of validation.¹³

Balancing Risk and Scientific Rigor

Let the consequence of a wrong result set the level of rigor. A marker used for an internal go/no-go decision may tolerate more uncertainty than one used to determine treatment eligibility. A risk-based plan focuses effort on the sources of variability most likely to change the decision.¹⁴

Aligning Study Design with Context of Use

Study design should serve the decision the biomarker will inform. For the treatment-response marker, investigators would select samples from the intended population, measure the marker before therapy, define the response endpoint and acceptance criteria in advance, and account for factors that could influence both marker levels and outcome. This alignment helps ensure that the resulting evidence supports the proposed clinical decision rather than a broader, less actionable association.¹⁴

Common Challenges in Biomarker Validation^2,15

Most validation failures are not caused by one dramatic mistake. They emerge when small weaknesses compound across samples, assays and study design. In the running example, any of the followingeach challenge could create the false impression thatdistort the same core conclusion: whether the blood-based marker truly identifies likely treatment responders:

• Sample variability: Differences in sample collection, processing, storage or biological characteristics can introduce variability and affect biomarker measurements
• Poor assay design: An assay that lacks adequate sensitivity, specificity or other performance characteristics can produce unreliable results
• Inconsistent study populations: Differences in patient characteristics, disease stages or treatment protocols can make biomarker findings difficult to interpret or reproduce
• Lack of reproducibility: Findings that cannot be consistently replicated across samples, laboratories or studies may limit confidence in the biomarker
• Misalignment between biomarker purpose and validation evidence: A biomarker may appear promising, but evidence that does not address the questions relevant to its application may limit its practical value

Best Practices for Strong Biomarker Validation³

The practical lesson isApplied to make the intended decision visible at every stage. For the treatment-response marker, that means keepingthese practices keep assay performance, patient selection, response endpoints and evidence requirements the proposed decision aligned from the first studyearliest studies through qualification.

• Define the intended use early: Establishing the biomarker's purpose at the outset helps guide study design, validation criteria and evidence requirements
• Separate analytical and clinical evidence clearly: Distinguishing assay performance from clinical relevance makes it easier to evaluate the strength and limitations of the biomarker evidence
• Use well-characterized samples and controls: Appropriate samples and controls help reduce variability and provide reliable benchmarks for assessing assay performance
• Design studies around the context of use: Study populations, endpoints and validation criteria should align with how the biomarker will be applied
• Document methods transparently: Clear documentation of methods, results, deviations and quality-control procedures supports confidence in the findings, especially for regulatory submissions

References

1. Ahmad A, Imran M, Ahsan H. Biomarkers as biomedical bioindicators: approaches and techniques for the detection, analysis, and validation of novel biomarkers of diseases. Pharmaceutics 2023;15(6):1630.
2. Ou F-S, Michiels S, Shyr Y, Adjei AA, Oberg AL. Biomarker discovery and validation: statistical considerations. J Thorac Oncol 2021;16(4):537-545.
3. Nakayasu ES, Gritsenko M, Piehowski PD, Gao Y, Orton DJ, Schepmoes AA, et al. Tutorial: best practices and considerations for mass-spectrometry-based protein biomarker discovery and validation. Nat Protoc 2021;16(8):3737-3760.
4. Jiang Z, Zhang H, Gao Y, Sun Y. Multi-omics strategies for biomarker discovery and application in personalized oncology. Mol Biomed 2025;6(1):115.
5. Paver EC, Morey AL. Biomarkers and biomarker validation: a pathologist's guide to getting it right. Pathology 2024;56(2):147-157.
6. Bakker E, Hendrikse NM, Ehmann F, Van der Meer DS, Llinares Garcia J, Vetter T, et al. Biomarker qualification at the European Medicines Agency: a review of biomarker qualification procedures from 2008 to 2020. Clin Pharmacol Ther 2022;112(1):69-80.
7. Teunissen CE, Verberk IM, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, et al. Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. Lancet Neurol 2022;21(1):66-77.
8. Seyfinejad B, Jouyban A. Importance of method validation in the analysis of biomarker. BSP direct; 2022:567-569.
9. Abel A, Chambers A, Fill J, Reiske H, Lu M, Morris A, et al. Analytical validation and performance of a blood-based P-tau217 diagnostic test for Alzheimer disease. JALM 2025;10(3):533-545.
10. Saito K, Goda R, Arai K, Asahina K, Kawabata M, Uchiyama H, et al. Interlaboratory Evaluation of LC–MS-Based Biomarker Assays. Bioanalysis 2024;16(6):389-402.
11. Clark AJ, Lillard Jr JW. A comprehensive review of bioinformatics tools for genomic biomarker discovery driving precision oncology. Genes 2024;15(8):1036.
12. Hendrikse NM, Llinares Garcia J, Vetter T, Humphreys AJ, Ehmann F. Biomarkers in medicines development—from discovery to regulatory qualification and beyond. Front Med 2022;9:878942.
13. Hickford ES, Dejager L, Yuill D, Kotian A, Shankar S, Staelens L, et al. A biomarker assay validation approach tailored to the context of use and bioanalytical platform. Bioanalysis 2023;15(13):757-771.
14. Lord S, Horvath A, Sandberg S, Monaghan P, M. Cobbaert C, Reim M, et al. Is this test fit-for-purpose? Principles and a checklist for evaluating the clinical performance of a test in the new era of in vitro diagnostic (IVD) regulation. Crit Rev Clin Lab Sci 2025;62(3):182-197.
15. Li S, Looby N, Chandran V, Kulasingam V. Challenges in the metabolomics-based biomarker validation pipeline. Metabolites 2024;14(4):200.